These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 30604183)

  • 1. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
    Rootman JM; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Polito V; Bourzat F; Walsh Z
    Sci Rep; 2021 Nov; 11(1):22479. PubMed ID: 34795334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
    Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M
    J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.
    Prochazkova L; Lippelt DP; Colzato LS; Kuchar M; Sjoerds Z; Hommel B
    Psychopharmacology (Berl); 2018 Dec; 235(12):3401-3413. PubMed ID: 30357434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelic Microdosing: A Subreddit Analysis.
    Lea T; Amada N; Jungaberle H
    J Psychoactive Drugs; 2020; 52(2):101-112. PubMed ID: 31648596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic study of microdosing psychedelics.
    Polito V; Stevenson RJ
    PLoS One; 2019; 14(2):e0211023. PubMed ID: 30726251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.
    Kaertner LS; Steinborn MB; Kettner H; Spriggs MJ; Roseman L; Buchborn T; Balaet M; Timmermann C; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2021 Jan; 11(1):1941. PubMed ID: 33479342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdosing with classical psychedelics: Research trajectories and practical considerations.
    Wong A; Raz A
    Transcult Psychiatry; 2022 Oct; 59(5):675-690. PubMed ID: 36317302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC
    Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.
    Kaypak AC; Raz A
    Transcult Psychiatry; 2022 Oct; 59(5):665-674. PubMed ID: 36031848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.
    Andersson M; Kjellgren A
    Harm Reduct J; 2019 Nov; 16(1):63. PubMed ID: 31779667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field.
    Polito V; Liknaitzky P
    Neurosci Biobehav Rev; 2022 Aug; 139():104706. PubMed ID: 35609684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
    Fadiman J; Korb S
    J Psychoactive Drugs; 2019; 51(2):118-122. PubMed ID: 30925850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.